RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis

Abstract Background Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC....

Full description

Bibliographic Details
Main Authors: Zhongbo Li, Peng Su, Yinlu Ding, Honglei Gao, Huijie Yang, Xin Li, Xiao Yang, Yan Xia, Chenmiao Zhang, Mingxi Fu, Dehai Wang, Ye Zhang, Shu Zhuo, Jian Zhu, Ting Zhuang
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Cell Communication and Signaling
Subjects:
RBCK1
YAP
Breast cancer
Ubiquitin
Online Access:https://doi.org/10.1186/s12964-022-00963-8

Similar Items

Similar Items